Methotrexate induces cell swelling and necrosis in renal tubular cells

Pediatric Blood and Cancer

Volumn 46, Issue 5, 2006, Pages 624-629

  Grönroos, Marika ^a   Chen, Ming ^b   Jahnukainen, Timo ^a   Capitanio, Arrigo ^b   Aizman, Roman I ^c   Celsi, Gianni ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NOVOSIBIRSK STATE PEDAGOGICAL UNIVERSITY   (Russian Federation)

Author keywords

LLC PK1 cells; Methotrexate; Paediatric cancer patients; Side effects

Indexed keywords

AMILORIDE; ANTIPORTER; CARBACHOL; METHOTREXATE; TRYPAN BLUE;

ALKALINIZATION; ANIMAL CELL; ARTICLE; CANCER; CELL DEATH; CELL SWELLING; CELL VIABILITY; CHRONIC INFLAMMATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; KIDNEY TUBULE CELL; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

AMILORIDE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL SIZE; CELL SURVIVAL; KIDNEY TUBULES, PROXIMAL; LLC-PK1 CELLS; METHOTREXATE; NECROSIS; SODIUM CHANNEL BLOCKERS; SWINE;

EID: 33645278063     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20471     Document Type: Article

References (47)

1. Bleyer WA. The clinical pharmacology of methotrexate: New applications of an old drug. Cancer 1978;41:36-51.
2. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19:292-315.
3. Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary cns lymphoma. Neurology 2002;58:1513-1520.
4. Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary ens lymphomas. Br J Cancer 2004;90:353-358.
5. Geis T, Peters O, Friedrich M, et al. Intratumoral methotrexate kinetics in a patient with intracranial anaplastic ependymoma. Pediatr Blood Cancer 2004;43:78-80.
6. Joannon P, Oviedo I, Campbell M, et al. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: Lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 2004;43:17-22.
7. Moe PJ, Holen A. High-dose methotrexate in childhood all. Pediatr Hematol Oncol 2000;17:615-622.
8. Raetz E, Perkins S, Davenport V, et al. B large-cell lymphoma in children and adolescents. Cancer Treat Rev 2003;29:91-98.
9. Skarby T, Jonsson P, Hjorth L, et al. High-dose methotrexate: On the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (all). Cancer Chemother Pharmacol 2003;51:311-320.
10. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996;42:1322-1329.
11. Ahern MJ, Smith MD, Roberts-Thomson PJ. Methotrexate hepatotoxicity: What is the evidence? Inflamm Res 1998;47:148-151.
12. Cutolo M, Seriolo B, Pizzorni C, et al. Methotrexate in psoriatic arthritis. Clin Exp Rheumatol 2002;20:S76-S80.
13. Fraser AG. Methotrexate: First-line or second-line immunomodulator? Eur J Gastroenterol Hepatol 2003;15:225-231.
14. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: Current status and future directions. Am J Gastroenterol 2003;98:530-537.
15. Vandell AG, DiPiro JT. Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. Pharmacotherapy 2002;22:613-620.
16. Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983;1:208-216.
17. Deray G, Khayat D, Cacoub P, et al. The effects of diltiazem on methotrexate-induced nephrotoxicity. Eur J Clin Pharmacol 1989;37:337-340.
18. Fabbri A, Motta E, Ferrari S, et al. High-dose methotrexate treatment and liver function in patients with osteosarcoma. J Intern Med 1994;236:209-214.
19. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001;24:19-38.
20. Thierry FX, Vernier I, Dueymes JM, et al. Acute renal failure after high-dose methotrexate therapy. Role of hemodialysis and plasma exchange in methotrexate removal. Nephron 1989;51:416-417.
21. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100:2222-2232.
22. Murry DJ, Synold TW, Pui CH, et al. Renal function and methotrexate clearance in children with newly diagnosed leukemia. Pharmacotherapy 1995;15:144-149.
23. Rask C, Albertioni F, Bentzen SM, et al. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia - a logistic regression analysis. Acta Oncol 1998;37:277-284.
24. Maiche AG, Lappalainen K, Teerenhovi L. Renal insufficiency in patients treated with high dose methotrexate. Acta Oncol 1988;27:73-74.
25. Thyss A, Milano G, Kubar J, et al. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986;1:256-258.
26. Fuskevag OM, Kristiansen C, Olsen R, et al. Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate. Ultrastruct Pathol 2000;24:325-332.
27. Perazella MA. Crystal-induced acute renal failure. Am J Med 1999;106:459-465.
28. Pitman SW, Frei E, III. Weekly methotrexate-calcium leucovorin rescue: Effect of alkalinization on nephrotoxicity; pharmacokinetics in the ens; and use in ens non-Hodgkin's lymphoma. Cancer Treat Rep 1977;61:695-701.
29. Raso V, Schreiber R. A rapid and specific radioimmunoassay for methotrexate. Cancer Res 1975;35:1407-1410.
30. Fuskevag OM, Kristiansen C, Lindal S, et al. Leucovorin and maximum tolerated dose toxicity of methotrexate in rats. Pediatr Hematol Oncol 2000;17:651-658.
31. Fox RM. Methotrexate nephrotoxicity. Clin Exp Pharmacol Physiol 1979;5:43-45.
32. Kovacs GT, Paal C, Somlo P, et al. Proteinuria due to suboptimal hydration with high-dose methotrexate therapy. Cancer Chemother Pharmacol 1993;33:262-263.
33. Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 1981;19:453-456.
34. Seidel H, Moe PJ, Nygaard R, et al. Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. Pediatr Hematol Oncol 1994;11:165-172.
35. Skarin AT, Zuckerman KS, Pitman SW, et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including ens involvement. Blood 1977;50:1039-1047.
36. Hempel L, Misselwitz J, Fleck C, et al. Influence of high-dose methotrexate therapy (hd-mtx) on glomerular and tubular kidney function. Med Pediatr Oncol 2003;40:348-354.
37. el-Badawi MG, Abdalla MA, Bahakim HM, et al. Nephrotoxicity of low-dose methotrexate in guinea pigs: An ultrastructural study. Nephron 1996;73:462-466.
38. Kinugawa N, Okimoto Y, Teraoka N, et al. Report of a patient with a high level of parathyroid hormone-related peptide associated with malignant lymphoma involving multiple bony lesions. Nephron 2002;90:103-105.
39. Chen M, Bao W, Aizman R, et al. Activation of extracellular signal-regulated kinase mediates apoptosis induced by uropathogenic Escherichia coli toxins via nitric oxide synthase: Protective role of heme oxygenase-1. J Infect Dis 2004;190:127-135.
40. Aquerreta I, Aldaz A, Giraldez J, et al. Pharmacodynamics of high-dose methotrexate in pediatric patients. Ann Pharmacother 2002;36:1344-1350.
41. Smeland E, Fuskevag OM, Nymann K, et al. High-dose 7-hydromethotrexate: Acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol 1996;37:415-422.
42. Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology 2000;47:247-257.
43. Von Hoff DD, Penta JS, Helman LJ, et al. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 1977;61:745-748.
44. Kopecna L. Late effects of anticancer therapy on kidney function in children with acute lymphoblastic leukemia. Bratisl Lek Listy 2001;102:357-360.
45. Taub JW, Ge Y. Down syndrome, drug metabolism, and chromosome 21. Pediatr Blood Cancer 2005;44:33-39.
46. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-2614.
47. Okada Y, Maeno E, Shimizu T, et al. Receptor-mediated control of regulatory volume decrease (rvd) and apoptotic volume decrease (avd). J Physiol 2001;532:3-16.